Numis Securities Ltd Reiterates Hold Rating for Smith & Nephew plc (SNN)
A number of other firms have also recently commented on SNN. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Monday. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Monday. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Monday. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Smith & Nephew plc presently has a consensus rating of “Buy” and an average target price of $97.00.
Shares of Smith & Nephew plc (NYSE:SNN) traded up 0.10% during mid-day trading on Monday, hitting $89.50. 138,154 shares of the company’s stock traded hands. Smith & Nephew plc has a 1-year low of $57.99 and a 1-year high of $100.90. The stock’s 50-day moving average is $89.2 and its 200-day moving average is $80.81. The company has a market cap of $16.003 billion and a price-to-earnings ratio of 30.78.
Smith & Nephew plc (NYSE:SNN) last released its earnings data on Friday, August 1st. The company reported $1.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.08. Analysts expect that Smith & Nephew plc will post $4.14 EPS for the current fiscal year.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.